What is Survodutide?
Survodutide (BI 456906) is an investigational dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim. Unlike tirzepatide (GLP-1/GIP dual agonist), survodutide combines GLP-1 with glucagon receptor activation — a different dual-agonist approach that emphasizes hepatic fat oxidation.
Mechanism: GLP-1 + Glucagon
Survodutide’s unique receptor profile targets appetite suppression (GLP-1) and hepatic metabolism (glucagon). The glucagon component promotes liver fat oxidation, making survodutide particularly relevant for research on hepatic steatosis and NASH.
Clinical Trial Status
Phase 2 trials demonstrated significant metabolic improvements with survodutide, particularly in liver fat reduction. Phase 3 trials are underway for multiple metabolic indications.
Comparison with Other GLP-1 Compounds
Survodutide occupies a unique space: it shares the glucagon component with retatrutide (triple agonist) but lacks the GIP receptor activation. This makes it useful for isolating GLP-1/glucagon effects from GIP-mediated effects in research. See GLP-1 triple comparison.
For research and educational purposes only. Catalog | COAs